Respiratory syncytial virus is the leading cause of hospitalization among U.S. infants. A vaccine, nirsevimab, can reduce the ...

The new research, published Monday (Dec. 9) in the journal JAMA Pediatrics, focused on nirsevimab (Beyfortus), a drug approved in 2023. The medicine, which is given as an injection, uses lab-made ...

Nirsevimab is a monoclonal antibody crucial for preventing severe RSV in infants and young children. A nationwide shortage prompted a revised allocation strategy prioritizing VFC-eligible infants ...

More information: Heidi L. Moline et al, Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024, JAMA Pediatrics (2024). DOI: 10.1001 ...

The monoclonal antibody nirsevimab, though not a vaccine, is approved by the FDA for the prevention of RSV lower respiratory ...

RSV cases drop in Alaska's Yukon-Kuskokwim region, Ketchikan airport parking is tight, hunters urged to try lead-free ammo, ...

This analysis documented the continued high burden of medically attended respiratory syncytial virus (RSV)-associated acute respiratory illness among young children in the U.S. Nirsevimab and ...

As the respiratory illness season begins, cases of respiratory syncytial virus (RSV) cases are rising in Canada. But new tools offers hope for prevention.

Nirsevimab is made by AstraZeneca and distributed in Canada by Sanofi, under the name Beyfortus. The single injection protects infants through the fall and winter when RSV circulates regularly (as ...

In a new study, the RSV drug nirsevimab was 93% effective at preventing young children from being hospitalized for the respiratory infection. A new RSV drug designed to protect young children was ...

Nirsevimab demonstrated 89% effectiveness against medically attended RSV-associated acute respiratory illness and 93% effectiveness against RSV-associated hospitalizations, although only 442 ...